The prevalence of hypertriglyceridaemia is high and growing in several parts of the world. Hypertriglyceridaemia has a well-defined association with the risk of atherosclerotic cardiovascular (CV) disease and triglycerides represent a potential target for drugs aimed at mitigating CV risk. So far, no triglyceride-lowering pharmacological strategy has succeeded in conclusively showing the ability to modify clinical outcomes. This article discusses strategic and clinical aspects of development of triglyceride-lowering drugs to address CV disease.
Introduction
The global burden of cardiovascular (CV) disease is still growing despite the progress made over the last decades in developing and implementing preventive and therapeutic strategies. Heart disease and stroke will result in an estimated 24 million annual deaths worldwide by 2030. 1 Continued therapeutic innovation to prevent and treat CV disease remains an important medical need. An increasingly significant driver of atherosclerotic CV disease is the growing prevalence of obesity and its metabolic manifestations such as insulin resistance, type 2 diabetes mellitus, non-alcoholic fatty liver disease, and hypertriglyceridaemia. Since 1976, the prevalence of elevated low-density lipoprotein (LDL) cholesterol in the US has decreased from 59% to 27% (2007-2010) primarily due to public health initiatives to reduce cholesterol intake and the growing use of statin therapy. 2 But even as LDL cholesterol levels have fallen, the proportion of adults with hypertriglyceridaemia has grown. In surveys from the US and Europe, the prevalence of adults with hypertriglyceridaemia has been found to be 33% and 29%, respectively. 3, 4 In the developing parts of the world, the prevalence of hypertriglyceridaemia is even higher than in Western countries. This trend is expected to continue, driven by the looming pandemic of diabetes and its associated metabolic manifestations foreshadowed by population studies. 5, 6 Although there are signs that average triglyceride levels have recently stabilized, and even begun to fall in some developed countries, the prevalence of the underlying metabolic drivers of obesity and hyperglycaemia appears to increase. [7] [8] [9] These trends have important clinical implications because persistent hypertriglyceridaemia signals significant residual CV risk, even in patients with well-controlled LDL cholesterol levels achieved by high-intensity statin regimens. [10] [11] [12] [13] Disappointingly, no triglyceride-lowering therapy has so far been successful in reducing the risk of CV events in double-blind, randomized trials in patients already on statin therapy. 14, 15 This has led many to conclude that triglycerides are not a valid target of intervention. However, failure to successfully modify CV risk by targeting triglycerides may be attributed to multiple mechanisms other than the therapeutic relevance of the target per se, such as inherent properties of the molecules tested or deficiencies in the design and execution of the development programs. This article argues that addressing hypertriglyceridaemia to address residual CV risk still holds promise if the right drug is tested in the right patient population. Regulatory, clinical, and operational challenges in the design and execution of development programs of novel triglyceride-lowering therapies will be discussed with an emphasis on late-stage clinical development.
The case for targeting triglycerides
A dysregulated triglyceride metabolism is characterized by an increased hepatic production and reduced peripheral clearance of triglycerides, and a consequent increase in circulating levels of triglyceride-rich lipoproteins both in the fasting state and in the postprandial period. The cholesterol contained in these triglyceride-rich lipoproteins is the primary substrate for the atherogenicity associated with hypertriglyceridaemia. Non-high-density lipoprotein (non-HDL) cholesterol or apolipoprotein B are both markers that reflect the totality of the atherogenic cholesterol, while measurement of LDL cholesterol does not capture the cholesterol contained on the triglyceride-rich particles and thus will underestimate cholesteroldriven risk in hypertriglyceridaemic conditions. Through multiple mechanisms hypertriglyceridaemia drives other closely related downstream quantitative and qualitative changes in lipoproteins such as reduced high-density lipoprotein (HDL) cholesterol and development of small and dense LDL particles. This lipid pattern is known as atherogenic dyslipidaemia. Consistent with the intimate relationship between triglycerides and the different lipoproteins, interventions to lower triglycerides usually also confer a positive impact on atherogenic dyslipidaemia as a whole. Despite the mechanistic link and the steep risk gradient defined by triglyceride levels in epidemiological datasets and observational analyses of randomized trials, the extent to which hypertriglyceridaemia directly promote atherosclerosis, and thus triglyceride's relevance as a therapeutic target, is still disputed. [10] [11] [12] [13] 16, 17 The controversy principally relates to two independent observations. First, randomized trials of triglyceride-lowering drugs on top of adequate statin therapy have consistently failed to demonstrate benefit. 14, 15 Second, when adjustment has been made for HDL levels in many observational analyses, the relationship between triglycerides and CV events is attenuated or disappears altogether. For the former, when considering the negative CV outcomes trials that have tested triglyceride-lowering drugs on top of statin therapy, it is relevant to note that none of the studies exclusively studied patients with elevated triglycerides, but rather included broader dyslipidaemia populations. From a biological standpoint, it is perhaps to be expected that drugs which primarily modulate triglyceride metabolism may not confer clinical benefits in patients where that specific pathobiology (i.e. hypertriglyceridaemia) is not active. In support of this interpretation, subgroup analyses from outcome trials demonstrate benefit in patients with elevated triglycerides or elevated triglycerides coupled with low HDL cholesterol (see below). [18] [19] [20] [21] For the latter, the observational data on triglycerides and CV disease should be considered in context of the limitations of traditional epidemiology in elucidating closely interdependent biological relationships such as that which exists between triglycerides, non-HDL cholesterol, and HDL cholesterol. Complexity is increased further by the fact that triglycerides exhibit a large intra-individual variability that increases with higher values. Novel analytical approaches, such as Mendelian randomization, which avoid many of the pitfalls of traditional observational analyses, strongly implicate triglyceridemediated pathways in the development of CV disease. 22 Variations in the expression of at least three different genetic determinants of triglyceride levels, ANGPTL4, APOCIII, and APOA5, all consistently demonstrate an association with CV events. [23] [24] [25] [26] Taken together, multiple lines of evidence support the causal link between elevated triglycerides and atherosclerotic CV disease.
Regulatory challenges
Both US and European regulators have historically granted approval for lipid-altering drugs based on lipid reduction alone without requiring demonstration of reductions in clinical outcomes. All eight statins that at some point have been available in the US or Europe received full approval on the basis of LDL cholesterol reductions. These approvals have rested on the assumption that the observed lipid responses are surrogate markers for prospective CV risk.
During the last 10 years legitimate concerns have been raised with respect to the use of surrogate endpoints as the basis for approval of lipid-altering drugs. The skepticism has been fuelled by a number of high-profile outcome trials within the CV space unable to demonstrate translation of favourable metabolic or lipid effects into clinical benefit. [27] [28] [29] In some cases, outcome trials have also revealed a paradoxical increase in CV risk. 30 Regulators have appropriately responded to these developments by requiring that companies generate more evidence prior to approval to provide a more precise estimate of the benefit-risk balance of novel interventions. Even though LDL lowering drugs may still be approved under specific circumstances based on LDL cholesterol reductions, drugs targeted primarily at other lipid markers need to be supported by a completed CV outcomes trial for approval. In sum, these developments have raised the bar for approval of novel lipid-modulating drugs considerably and added complexity and uncertainty to an already challenging drug development process.
Strategies to de-risk clinical development
In some therapeutic indications, preliminary evidence of human efficacy may be determined relatively quickly using clinical or biomarker endpoints in Phase 2 or even Phase 1b. Such early go/no go decisions are critical in the drug development process to manage and prioritize resources across the drug development portfolio of pharmaceutical companies. However, owing to the lack of reliable surrogate endpoints for lipid-modulating drugs, Phase 2 usually offers limited derisking opportunity which means that a substantial portion of the overall risk will not be resolved until very late in the development cycle. Phase 2 programs are therefore often primarily designed to collect safety and dose-response data, with no clinical efficacy based go/no go decision points in order to quickly enable an initiation of a Phase 3 CV outcomes trial. Some development programs have attempted to reduce risk and improve predictability by progressing more carefully in a staggered fashion with comprehensive Phase 2 programs designed to capture an earlier indication of anti-atherosclerotic efficacy. The principal challenge lies in identifying and validating intermediate surrogate endpoints on the causal pathway between lipid modulation and clinical events, and then subsequently to integrate them in a timely manner into the strategic decision-making process. The only technology currently available that realistically may fulfil these requirements is direct visualization of anti-atherosclerotic effects through various imaging modalities. 31 In practice, because demonstration of anti-atherosclerotic effects of lipid-modulating therapies usually will require at least 1 year of treatment, these studies are often performed as part of a development program, but are rarely used explicitly as a de-risking strategy. Even when an imaging study is an integrated part of the development program, it may still be regarded as insufficiently reliable to be used as the basis for a go/no go decision on completion of the Phase 2 trial. Genetic analyses offer novel ways to validate biological targets. For triglycerides specifically, several potential targets have been suggested by such genetic studies. [17] [18] [19] [20] [21] [22] [23] [24] [25] 
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Adaptive licencing is another concept that can partially offset the back-loaded risk of a CV outcomes trial. A staggered registration strategy enhances the efficiency of the development cycle by initially targeting niche indications with a very high unmet need requiring less clinical data for approval. There are several examples of companies developing triglyceride-lowering drugs pursuing such an adaptive licencing strategy by seeking an initial approval for smaller indications in parallel to the ongoing development for CV risk reduction. For example, a development program to support approval for severe hypertriglyceridaemia (> 500 mg/dL) to prevent pancreatitis represents a quicker and less complex clinical and regulatory path to approval, and therefore potentially decreases the time to market entry in some geographies significantly. The earlier product revenues will in turn partially offset some of the risk attached to the comprehensive CV development program. Importantly, an earlier market entry will also ensure collection of real-world data that will reveal potential issues, if any, and also help address other questions that may have arisen during development.
Considerations for clinical outcome trials
Assuming a novel therapy reduces the risk of CV events by 15-25% in a secondary or high-risk primary prevention setting on top of statin therapy, at least 8000 patients treated for several years are required to be reasonably certain that the hypothesized benefit of the intervention will be demonstrated in a statistically robust fashion. Such trials will run up costs of many hundred millions of US dollars and may account for 50% or more of the total investment in a development program of any New Chemical Entity. The importance of thoughtfully designed, high-quality Phase 3 trials is therefore self-evident. The trial must be designed to test the underlying biological rationale, but should also take into account what is operationally and economically feasible. Importantly, the design should integrate high scientific standards and adhere to strict regulatory requirements, but also accept pragmatic elements in the face of treatment practices that fall short of guideline recommendations. Successful development programs are able to balance all of these equities to produce data of high scientific integrity that are in line with regulatory demands, as well as medically relevant and applicable in daily clinical practice. Some of the key protocol considerations are discussed below.
Selection of subjects
Selection of the appropriate patient population is a critical component of any successful Phase 3 trial. The ACCORD study found that the combination of fenofibrate and simvastatin did not reduce the risk of a composite endpoint of CV events when compared to simvastatin alone in patients with type 2 diabetes mellitus. 15 But in the same trial, those patients who presented with elevated triglycerides (>204 mg/dL) and low HDL-C (<34 mg/dL) at inclusion demonstrated a 31% reduction of risk of the composite endpoint (P for interaction = 0.06). 18 Subgroup analyses, particularly of negative studies, should always be interpreted with caution. Nevertheless, the ACCORD results are consistent with the pattern seen in other trials of multiple pharmacological agents targeting atherogenic dyslipidaemia, such as niacin (AIM-HIGH), omega-3 fatty acid (JELIS), and gemfibrozil (Helsinki Heart Study). [19] [20] [21] Taken together, these data lend support to the notion that future CV outcomes studies testing the clinical benefit of triglyceride-lowering interventions should specifically target patients with elevated triglycerides, and potentially other features of atherogenic dyslipidaemia. Once criteria have been included to ensure selection of relevant patients from a biological standpoint (i.e. with modifiable risk) consideration should also be paid to enrich for patients with a high absolute risk. This is usually ensured by targeting secondary prevention populations and/or populations with high-risk clinical features such as type 2 diabetes mellitus. However, the use of biomarkers could help refine enrichment further by identifying patients at very high risk of events both in primary and secondary prevention populations. An example of such a biomarker is cardiac troponin. Cardiac troponin T and I are specific to the heart and elevations reflect ongoing myocardial injury. In the SAVOR-TIMI trial in patients with type 2 diabetes mellitus, the investigators found a stepwise increase in rates of myocardial infarction (MI) and CV death with higher quartiles of cardiac troponin T at baseline. 38 Interestingly, patients without established clinical CV disease at baseline, but with troponin T elevations above the 99th percentile, had a higher prospective CV risk than patients with established CV disease at baseline without cardiac troponin T elevations. Therefore, one may speculate that using elevation in troponin T as an inclusion criterion in patients with hypertriglyceridaemia will lead to levels of CV events that may result in a more acceptable sample size and trial duration, although this must be balanced against the risk of slower enrolment rates and higher screen failure numbers.
Selection of endpoints
Cardiovascular outcome studies of lipid-modulating drugs are usually designed to reach a pre-defined number of primary endpoint events (i.e. event-driven). The need for a high number of events has led to the development of composite endpoints which further add to the complexity of the trial and the interpretation of the results. Lipid trials usually combine CV death, MI, and stroke as these endpoints are likely modifiable by a lipid-modulating intervention and can be defined by objective criteria. However, the infeasibility and high cost of recruiting sufficient number of patients to accrue the needed events, have led to the inclusion of softer endpoints such as hospitalization for unstable angina and revascularization procedures. These endpoints are more prone to ambiguity and bias but are nonetheless accepted by regulators as part of a composite primary endpoint. With very few exceptions, all of the major lipid trials recently completed or underway use an extended CV primary endpoint.
Event rates and effect size
The size and duration of the study is determined primarily by the estimated event rates in the control group and the postulated effect size of the intervention. The estimated annual event rate for an expanded composite endpoint in a typically high-risk CV population may be approximately 5-6% based on contemporary trials. Effect size assumptions are challenging to estimate for triglyceride-lowering interventions due to the complex biological interdependencies of lipids and lipoproteins. The reduction in apolipoprotein B or non-HDL cholesterol observed in the Phase 2 trial(s) may be used as a guide. An approximate 1:1 relationship between reduction in non-HDL cholesterol and CV events exists for both statins and fibrates. 39 Consistent with the reduction in triglyceride-rich lipoproteins, triglyceride-lowering drugs also lower non-HDL cholesterol, and apolipoprotein B to varying degrees. A partial or almost complete correction of a dysregulated triglyceride metabolism, which includes reductions in levels of triglycerides and remnant cholesterol and an increase in larger, less atherogenic LDL particles, may be associated with a larger effect size than judged by the non-HDL cholesterol reduction alone, but this remains speculative.
Study duration and retention of patients
The CV protection conferred by lipid modulation may take several years to become clinically apparent. This is unlike for example antithrombotic drugs where an immediate reduction in events is often seen. Thus, each patient ideally should be treated for an extended period, and at the very least 1.5-2 years. This means that the trial overall usually must run for 4 or more years which poses challenges to the retention of patients. A high number of trial patients lost-to-follow-up may compromise the integrity and interpretability of the results. To have regulators call into question the reliability of an entire trial based on poor patient-retention is a catastrophic outcome for both sponsors, investigators, and patients. Patients who comply with follow-up visits but discontinue study drug is less of an issue with regulators (in a superiority trial), but it will dilute the results and, as such, increase the chance of accepting the null hypothesis. The IMPROVE-IT trial investigated the addition of ezetimibe to simvastatin in acute coronary syndrome patients and ran for 9 years. 40 In total, more than 40% of the randomized patients discontinued study drug without having had a primary endpoint or died. Despite the large proportion of discontinuations, the IMPROVE-IT trial did meet its primary endpoint of CV event reduction associated with addition of ezetimibe to simvastatin.
Challenges with global studies
In trials with global scope, regional differences in patient demographics, standard of care and patient education add complexity to the study design, study conduct, and interpretation of results. Differences between regions may interact with both efficacy and safety outcomes. For that reason, regulators often require a certain number of patients from their respective regions or countries. This may further complicate both the conduct and the scientific analysis of trials, as they are not statistically powered to allow a reliable interpretation of efficacy and safety in specific regions. A recent example in the CV area is the PLATO trial that tested the anti-thrombotic drug • Lipids:
• LDL-C <100 mg/dL • TG > _150 and <500 mg/dL
• Secondary prevention or high-risk primary prevention
• Lipids:
• LDL-C <100 mg/dL • TG > _180 and <500 mg/dL • HDL-C <42 mg/dL (men), HDL-C <47 mg/dL (women)
• 41 The trial overall met its primary endpoint of CV risk reduction with ticagrelor, but the results in the US and Canada were directionally different and favoured the comparator clopidogrel, which lead to uncertainty and extensive deliberations between the sponsor and regulators.
Current cardiovascular outcomes trials landscape for triglyceridelowering drugs
Three large CV outcomes studies of triglyceride-lowering compounds are currently underway ( Table 1) . [42] [43] [44] All three trials exclusively include subjects with elevated triglycerides, but there are important differences between the studies with regards to criteria for HDL cholesterol and study size. Two of the trials assess omega-3 fatty acids formulations and one trial tests the selective peroxisome proliferator activator receptor alpha agonist pemafibrate.
Summary and conclusion
Hypertriglyeridaemia and atherogenic dyslipidaemia are the most common lipid manifestation of the emerging metabolic profile associated with obesity and type 2 diabetes mellitus. Despite the strong association between hypertriglyceridaemia and risk of CV disease, elevation of triglycerides has until recently been considered an innocent bystander, a risk marker and not a risk factor, and as such a poor target for therapeutic interventions. Recent studies, particularly in the field of genetic epidemiology, have led many to revisit the role of triglycerides in the development of atherosclerosis and subsequently stimulated interest in drugs targeting triglyceride metabolism. This article has discussed some of the key challenges drug development programs must confront in the development of novel triglyceride-lowering drugs from a strategic, clinical, and operational standpoint. Despite the many hurdles and pitfalls, continued innovation is needed to address the residual CV risk associated with hypertriglyceridaemia.
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